Mdm2, p53 E3 Ubiquitin Protein Ligase Homolog (Mouse) (MDM2) antibody

Antigen: Mdm2, p53 E3 Ubiquitin Protein Ligase Homolog (Mouse) (MDM2)

Clonality: Polyclonal

Host: Rabbit

Reactivity: Mouse (Murine)

Conjugate: Un-conjugated

Application: ELISA, Western Blotting (WB)

Catalog no.: ABIN118010

Additional Information

Alternative name: MDM2

UniProt: P23804

Immunogen: Prepared from whole rabbit serum produced by repeated immunizations with a syntheticpeptide corresponding to aa 177-198 of mouse MDM2.

Cross-Reactivity: Mouse (Murine)

Description: MDM2 is a nuclear phosphoprotein with an apparent molecular mass of 90 kD that forms acomplex with the p53 tumor suppressor protein. Human MDM2 was identified as ahomologous product of the 'murine double minute 2' gene (mdm2). The MDM2 geneenhances the tumorigenic potential of cells when it is overexpressed and encodes aputative transcription factor. Forming a tight complex with the p53 gene, the MDM2oncogene can inhibit p53-mediated transactivation. MDM2 binds to p53 and amplificationof MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanismof tumorigenesis parallels that for virusinduced tumors in which viral oncogene productsbind to and functionally inactivate p53. Overexpression of the MDM2 oncogene was foundin leukemias. Inactivation of tumor suppressor genes leads to deregulated cellproliferation and is a key factor in human tumorigenesis. MDM2 interacts physically andfunctionally with the retinoblastoma (RB) protein and can inhibit its growth regulatorycapacity. Both RB and p53 can be subjected to negative regulation by the product of asingle cellular protooncogene. The interference of binding to p53 prevents the interactionof MDM2 and its regulation of the transcriptional activity of p53 in vivo. Direct associationof p53 with the cellular protein MDM2 results in ubiquitination and subsequentdegradation of p53. MDM2-p53 complexes were preferentially found in S/G2M phases ofthe cell cycle. The MDM2 gene is alternatively spliced, producing 5 additional splice varianttranscripts from the full length MDM2 gene. Four out of five of these alternatively splicedforms (MDM2a-MDMd) are missing substantial portions of the p53 binding domain andretain the acidic domain and the zinc-finger domains. The fifth and smallest transcript(MDM2e) retains the largest spliced region encoding the p53 binding domain, however, itlacks the nuclear localization signal, the acidic domain and zinc-finger domains. Thealternatively spliced transcripts tend to be expressed in tumorigenic tissue, whereas thefull-length MDM2 transcript is expressed in normal tissue.

Characteristics: Synonyms: p53-binding protein Mdm2, Oncoprotein Mdm2, Double minute 2 protein, Hdm2, E3ubiquitin-protein ligase Mdm2

Application Details

Application Notes: This affinity purified antibody has been tested for use in ELISA (1: 3,000 to 1: 12,000) andWestern blotting (1/500-1: 2,000). Western blotting shows specific banding forphosphorylated MDM 2 showing a band at approximately 102 kD corresponding tophosphorylated mouse MDM2. (See ref.5) for a discussion on expected molecular weights. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Concentration: 0.33 mg/ml (by UV absorbance at 280 nm)

Purification: Affinity Purified

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2, containing0.01% (w/v) Sodium Azide as preservative.

Storage: Store vial at -20°C prior to opening. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20°C or below. Avoid cycles of freezing and thawing. Shelf life: one year from despatch.

Research Area: Cancer, Cell Cycle, Transcription Factors

Restrictions: For Research Use only

Images

Immunoblotting. Affinity Purified Anti-MDM2 pS185 (Rabbit) is shown to detect a 102 kDa band (arrow) corresponding to phosphorylated mouse MDM2 present in a 293T whole cell lysate. Cells were serum-starved for 24 hours prior to harvest. Approximately 20 ug of lysate was loaded per lane for SDSPAGE. Untreated cells are shown in lane 1, whereas cells in lane 2 were treated with IGF-1 (100 ng/ml) for 20 min prior to harvest. Follow reaction of antibody with a 1:2000 dilution of HRP Goat-a-Rabbit IgG for visualization.

Publications

Widimsky, Straka, Stros et al.: "One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial." in: Circulation, Vol. 110, Issue 22, pp. 3418-23, 2004 (PubMed).

Pospisilova, Adam: "[Disorder of glucose metabolism regulation in patients with multiple myeloma treated with high doses of corticosteroids at our clinic in 2004]" in: Vnitr?ní lékar?ství, Vol. 53, Issue 1, pp. 18-23, 2007 (PubMed).